1. Home
  2. BNR vs RDIB Comparison

BNR vs RDIB Comparison

Compare BNR & RDIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Burning Rock Biotech Limited

BNR

Burning Rock Biotech Limited

HOLD

Current Price

$16.20

Market Cap

252.7M

Sector

Health Care

ML Signal

HOLD

RDIB

Reading International Inc Class B

HOLD

Current Price

$9.90

Market Cap

224.9M

ML Signal

HOLD

Company Overview

Basic Information
Metric
BNR
RDIB
Founded
2014
1937
Country
China
United States
Employees
N/A
2025
Industry
Medical Specialities
Movies/Entertainment
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
252.7M
224.9M
IPO Year
2019
N/A

Fundamental Metrics

Financial Performance
Metric
BNR
RDIB
Price
$16.20
$9.90
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
31.2K
4.7K
Earning Date
03-12-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$111.65
N/A
Revenue Next Year
N/A
$13.42
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.18
$7.61
52 Week High
$41.72
$17.40

Technical Indicators

Market Signals
Indicator
BNR
RDIB
Relative Strength Index (RSI) 35.63 42.20
Support Level $15.52 $8.87
Resistance Level $23.42 $12.53
Average True Range (ATR) 1.39 0.46
MACD -0.01 -0.06
Stochastic Oscillator 11.27 55.78

Price Performance

Historical Comparison
BNR
RDIB

About BNR Burning Rock Biotech Limited

Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through company's in-hospital model and smaller hospitals through its central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.

About RDIB Reading International Inc Class B

Reading International Inc is a diversified company, engaged in the development, ownership, and operation of multiplex cinemas and retail and commercial real estate in the United States, Australia, and New Zealand. It operates through two segments: the Cinema segment includes Reading Cinemas, Angelika Film Center, Consolidated Theatres, and City Cinemas; the Real Estate segment includes real estate development and the rental or licensing of retail, commercial and live theater assets.

Share on Social Networks: